Trans-AUCB

Trans-AUCB (t-AUCB) is a potent, orally active and selective soluble epoxide hydrolase (sEH) inhibitor with IC50s of 1.3 nM, 8 nM, 8 nM for hsEH, mouse sEH and rat sEH, respectively. trans-AUCB has anti-glioma activity[1][2].

Product Specifications

CAS Number

[885012-33-9]

Product Name Alternative

T-AUCB

UNSPSC

12352005

Target

Epoxide Hydrolase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/trans-aucb.html

Concentration

10mM

Purity

98.16

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC(C(C=C1)=CC=C1O[C@@H](CC2)CC[C@H]2NC(NC34C[C@H](C5)C[C@H](C[C@H]5C4)C3)=O)=O

Molecular Formula

C24H32N2O4

Molecular Weight

412.52

References & Citations

[1]Li J, et al. t-AUCB, an improved sEH inhibitor, suppresses human glioblastoma cell growth by activatingNF-κB-p65. J Neurooncol. 2012 Jul;108 (3) :385-93.|[2]Liu JY, et al. Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murinemodel of inflammation. Br J Pharmacol. 2009 Jan;156 (2) :284-96.